A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hirte, Holger
  • Vidal, L
  • Fleming, GF
  • Sugimoto, AK
  • Morgan, RJ
  • Biagi, JJ
  • Wang, L
  • McGill, S
  • Ivy, SP
  • Oza, AM

publication date

  • May 20, 2008